Citations

Mayo Clinic

Showing 10 of 108523 citations.

Total Joint Replacement: Lower Extremities†
Fitzgerald, Robert H.

Journal of the American Geriatrics Society | April 29, 2015 | Volume: 25 | Issue: 2 | Pages: 67-67

10.1111/j.1532-5415.1977.tb00232.x | PMID 833410 Get It

ABSTRACT In experience with total joint replacement in the lower extremity, to date, total hip arthroplasty has been the most successful. Total arthroplasty operations as applied to the knee and ankle are giving promising results. These methods offer new avenues for relief of pain and deformity and stabilization of arthritic joints in the lower extremity.
Examination of the Back in the Geriatric Patient†
Mayne, John G.

Journal of the American Geriatrics Society | April 29, 2015 | Volume: 25 | Issue: 2 | Pages: 59-61

10.1111/j.1532-5415.1977.tb00230.x | PMID 137923 Get It

ABSTRACT Older people often complain of back pain, but it usually is not a major complaint except in the presence of serious disease such as malignancy, compression fractures from osteoporosis, or disc‐space infections. When back pain is a serious symptom in the elderly patient, the physician should look beyond the obvious evidences of degenerative joint disease for these other more serious conditions. Satisfactory examination of the back does not require an undue amount of time. It is important that it be done systematically. Simple, rapid, and adequate procedures are described.
Intrasynovial Steroid Therapy: Uses and Abuses†
Fitzgerald, Robert H.

Journal of the American Geriatrics Society | April 29, 2015 | Volume: 25 | Issue: 2 | Pages: 57-58

10.1111/j.1532-5415.1977.tb00229.x | PMID 833409 Get It

ABSTRACT The indications and contraindications for use of intrasynovial steroid therapy are discussed. When properly used, the intrasynovial injection of steroids is a valuable method of treatment.
Differential Diagnosis of Rheumatic Disease in the Elderly†
O’Duffy, J. Desmond

Journal of the American Geriatrics Society | April 29, 2015 | Volume: 25 | Issue: 2 | Pages: 51-55

10.1111/j.1532-5415.1977.tb00227.x | PMID 299863 Get It

ABSTRACT To illustrate the diagnostic problems of rheumatic disease in patients over 60 years of age, 4 cases are presented: 1) osteoarthritis, 2) late‐onset rheumatoid arthritis, 3) polymyalgia rheumatica, and 4) pseudogout with crystalline synovitis. In each case the correct diagnosis should have been suspected from the history and physical examination alone, with the laboratory and x‐ray findings providing supportive evidence.
Section I. The Interpretation and Use of Newer Diagnostic Studies
Mayne, John G.

Journal of the American Geriatrics Society | April 29, 2015 | Volume: 25 | Issue: 2 | Pages: 49-50

10.1111/j.1532-5415.1977.tb00226.x | PMID 833408 Get It

ABSTRACT The diagnosis and the treatment of rheumatic diseases in older people pose special problems. Degenerative joint disease, almost universally present in the elderly, may not be the basis for the newly developing rheumatic symptoms. Systemic inflammatory disease may be confused with malignancy or it may be an initial manifestation of malignancy. Some drugs used to control central‐nervous‐system or cardiovascular disease may produce painful rheumatic syndromes. Results of laboratory tests used in the diagnosis of rheumatic diseases may be altered by other nonrheumatic disorders in older people. Papers in this symposium will explore these concepts in greater detail.
High functioning male with fragile X syndrome and fragile X‐associated tremor/ataxia syndrome
Basuta, Kirin, Schneider, Andrea , Gane, Louise W., Polussa, Jonathan, Woodruff, Bryan K. , Pretto, Dalyir, Hagerman, Randi J. , Tassone, Flora

American Journal of Medical Genetics Part A | April 29, 2015 | Volume: 167 | Issue: 9 | Pages: 2154-2161

10.1002/ajmg.a.37125 | PMID 25920745 Get It

Fragile X syndrome (FXS) affects individuals with more than 200 CGG repeats (full mutation) in the fragile X mental retardation 1 (FMR1) gene. Those born with FXS experience cognitive and social impairments, developmental delays, and some features of autism spectrum disorders. Carriers of a premutation (55–200 CGG repeats) are generally not severely affected early in life; however, are at high risk of developing the late onset neurodegenerative disorder, Fragile X‐associated Tremor/Ataxia Syndrome (FXTAS), or Fragile X‐associated Primary Ovarian Insufficiency (FXPOI), and may have other medical conditions such as developmental delay, autism spectrum disorders, hypertension, anxiety, and immune‐mediated disorders. Here we present a case of a 58‐year‐old man with a borderline IQ, average memory skills, and executive function deficits. He met criteria for multiple psychiatric diagnoses and presented with tremor and ataxia, meeting criteria for FXTAS. Molecular testing unveiled a completely unmethylated FMR1 full mutation in peripheral blood mononucleated cells with elevated FMR1 mRNA and premutation alleles of different sizes in two other tissues (primary fibroblasts and sperm), indicating the presence of allele instability based on both inter‐ and intra‐tissue mosaicism. The observation of FXTAS in this case of a full mutation mosaic man suggests that the pathogenic mechanism underlying this disorder is not observed exclusively in premutation carriers as it was originally thought. The concomitant presence of features of FXS and late onset neurological deterioration with probable FXTAS likely result from a combined molecular pathology of elevated FMR1 mRNA levels, a molecular hallmark of FXTAS and low FMRP expression that leads to FXS. © 2015 Wiley Periodicals, Inc.
Cybersecurity in Artificial Pancreas Experiments
O’Keeffe, Derek T. , Maraka, Spyridoula , Basu, Ananda, Keith-Hynes, Patrick, Kudva, Yogish C. , Maraka, Spyridoula

Diabetes Technology & Therapeutics | April 29, 2015 | Volume: 17 | Issue: 9 | Pages: 664-666

10.1089/dia.2014.0328 | PMID 25923544 Get It

Serum Concentrations of the Iodothyronines in Elderly Subjects: Decreased Triiodothyronine (T 3 ) and Free T 3 Index
Caplan, Robert H., Wickus, Gary G., Glasser, James E., Davis, Kent, Wahner, Heinz W.

Journal of the American Geriatrics Society | April 29, 2015 | Volume: 29 | Issue: 1 | Pages: 19-24

10.1111/j.1532-5415.1981.tb02388.x | PMID 7005294 Get It

ABSTRACT In four groups of subjects free of thyroid disease, the following determinations were made: serum concentrations of thyroxine (T 4 ), triiodothyronine (T 3 ), reverse T 3 (rT 3 ) and diiodothyronine (T 2 ), and calculated indices of free thyroxine (FT 4 ) and free triiodothyronine (FT 3 ). Group A comprised healthy subjects aged 16–64; Group B, 24 healthy elderly subjects aged 68–95; Group C, 23 elderly patients with mild well‐controlled chronic illnesses, aged 70–85; Group D, 40 nursing home residents aged 66–100. Serum T 4 and T 2 concentrations and the FT 4 index were not affected by age; the rT 3 concentration was slightly but significantly elevated only in Group D patients. Serum T 3 concentration was significantly lower in all groups of elderly subjects and decreased FT 3 index measurements were detected after age 75. It was concluded that old age, without complicating illness, is accompanied only by a decrease in the serum level of T 3 and the FT 3 index; values for other iodothyronines are unchanged. Clinicians should consider the age‐related changes in T 3 and FT 3 values when interpreting thyroid function tests.
Homozygous/Compound Heterozygous Triadin Mutations Associated With Autosomal-Recessive Long-QT Syndrome and Pediatric Sudden Cardiac Arrest
Altmann, Helene M., Tester, David J. , Will, Melissa L., Middha, Sumit , Evans, Jared M., Eckloff, Bruce W., Ackerman, Michael J.

Circulation | April 29, 2015 | Volume: 131 | Issue: 23 | Pages: 2051-2060

10.1161/circulationaha.115.015397 | PMID 25922419 Get It

Background— Long-QT syndrome (LQTS) may result in syncope, seizures, or sudden cardiac arrest. Although 16 LQTS-susceptibility genes have been discovered, 20% to 25% of LQTS remains genetically elusive. Methods and Results— We performed whole-exome sequencing child–parent trio analysis followed by recessive and sporadic inheritance modeling and disease-network candidate analysis gene ranking to identify a novel underlying genetic mechanism for LQTS. Subsequent mutational analysis of the candidate gene was performed with polymerase chain reaction, denaturing high-performance liquid chromatography, and DNA sequencing on a cohort of 33 additional unrelated patients with genetically elusive LQTS. After whole-exome sequencing and variant filtration, a homozygous p.D18fs*13 TRDN -encoded triadin frameshift mutation was discovered in a 10-year-old female patient with LQTS with a QTc of 500 milliseconds who experienced recurrent exertion-induced syncope/cardiac arrest beginning at 1 year of age. Subsequent mutational analysis of TRDN revealed either homozygous or compound heterozygous frameshift mutations in 4 of 33 unrelated cases of LQTS (12%). All 5 TRDN-null patients displayed extensive T-wave inversions in precordial leads V 1 through V 4 , with either persistent or transient QT prolongation and severe disease expression of exercise-induced cardiac arrest in early childhood (≤3 years of age) and required aggressive therapy. The overall yield of TRDN mutations was significantly greater in patients ≤10 years of age (5 of 10, 50%) compared with older patients (0 of 24, 0%; P =0.0009). Conclusions— We identified TRDN as a novel underlying genetic basis for recessively inherited LQTS. All TRDN-null patients had strikingly similar phenotypes. Given the recurrent nature of potential lethal arrhythmias, patients fitting this phenotypic profile should undergo cardiac TRDN genetic testing.
Longer‐term follow‐up and outcome by tumour cell proliferation rate (Ki‐67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL‐001(EMERGE) pivotal trial
Beşışık, Sevgi Kalayoğlu , Drach, Johannes, Ramchandren, Radhakrishnan , Avivi, Irit , Rowe, Jacob M. , Herbrecht, Raoul , Hoof, Achiel Van, Zhang, Lei , Cicero, Sherri, Goy, Andre Henri , Robertson, Michael J. , Fu, Tommy , Witzig, Thomas E.

British Journal of Haematology | April 29, 2015 | Volume: 170 | Issue: 4 | Pages: 496-503

10.1111/bjh.13456 | PMID 25921098 Get It

SummaryPatients with mantle cell lymphoma (MCL) generally respond to first‐line immunochemotherapy, but often show chemoresistance upon subsequent relapses, with poor outcome. Several studies of the immunomodulator, lenalidomide, have demonstrated its activity in MCL including the MCL‐001 study in relapsed/refractory patients who had failed defined prior therapies of anthracyclines or mitoxantrone, cyclophosphamide, rituximab and also bortezomib. We present here the long‐term efficacy follow‐up of the prospective phase II MCL‐001 study (N = 134), including new exploratory analyses with baseline Ki‐67 (MIB1), a biological marker of tumour proliferation. With longer follow‐up, lenalidomide showed a 28% overall response rate [ORR; 8% complete response (CR)/CR unconfirmed (CRu)]. Median duration of response (DOR), progression‐free survival and overall survival were 16·6, 4·0 and 20·9 months, respectively. Myelosuppression continued to be the most common grade 3/4 toxicity. Several studies of MCL patients treated with chemotherapy, rituximab and bortezomib have shown an inverse association between survival and Ki‐67. Ki‐67 data in 81/134 MCL‐001 patients showed similar ORRs in both low (<30% or <50%) versus high (≥30% or ≥50%) Ki‐67–expressing groups, yet lower Ki‐67 levels demonstrated superior CR/CRu, DOR and survival outcomes. Overall, lenalidomide showed durable efficacy with a consistent safety profile in heavily pretreated, relapsed/refractory MCL post‐bortezomib.